News
OSE Immunotherapeutics signs a license option agreement with Servier to develop and commercialize the product Effi-7
OSE Immunotherapeutics SA announced that the company has entered into a worldwide license option agreement with Servier, an independent international pharmaceutical company, for the development and commercialization of OSE Immunotherapeuticsโ Effi-7, an antagonist of the interleukin-7 receptor. ...
News
Saneca Pharma Expands R&D Capabilities
Contract development and manufacturing organization (CDMO) Saneca Pharma is driving forward with new research and development initiatives for the manufacture of active pharmaceutical ingredients (APIs) following a โฌ1.5 million grant from the Slovak Ministry of Education, Science, Research and...
News
Cerevance launched with new technology, drug portfolio and $36m in cash to tackle brain diseasesย
Takeda Pharmaceutical Company Limited and Lightstone Ventures announced the launch of Cerevance, a neuroscience company focused on discovering and developing novel therapeutics for neurological and psychiatric disorders. The company will use a new technology, created in...
News
Sun Pharma launches first branded ophthalmic product, BromSiteโข, in USA
Sun Pharma announced the launch of BromSiteโข (bromfenac ophthalmic solution) 0.075% in the US market.A nonsteroidal anti-inflammatory drug indicated for the treatment of postoperative inflammation and prevention of ocular pain in patients undergoing cataract surgery. ย ...
News
CeMAT, Industrial Automation and Motion Drive & Automation to redefine manufacturing technology in India
WIN INDIA 2016, Indiaโs leading industrial and engineering trade fair will bring together 3 key industrial trade fairs - CeMAT INDIA, Industrial Automation INDIA (IA India) and Motion Drive & Automation INDIA (MDA India). The events...
News
CPhI & P-MEC India gets bigger with an exclusive โIndia Pharma Week 2016โ
UBM India, India's leading exhibition organizer, is all set to host CPhI & P-MEC India 2016, one of the worldโs leading pharmaceutical networking event in Mumbai. In its tenth anniversary, the expo is slated to transform...
News
Biothera Pharmaceuticals Preclinical Data Further Validate Mechanism of its Phase 2 Cancer Immunotherapy, Imprime PGG
Biothera Pharmaceuticals Inc will present new preclinical data that further validate the ability of its Phase 2 cancer immunotherapy drug Imprime PGG to induce coordinated innate and adaptive immune responses that may enhance the efficacy of checkpoint inhibitor therapies....
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
















